The tweet was deleted by the author.
But we saved everything 🙂.
Twist Bioscience reports that AI engineering has enabled the creation of synthetic homologs of potentially dangerous biological sequences which can evade existing biosecurity screening systems by fragmenting them into smaller oligo segments.
Bruce Wittmann, Microsoft Research technical fellow Eric Horvitz, and James Diggans of Twist Bioscience, along with their teams, conducted a detailed examination of these vulnerabilities, highlighting how advances in artificial intelligence could challenge the efficacy of biosecurity oversight tools.
The rapid evolution of artificial intelligence in synthetic biology not only poses new challenges for biosecurity frameworks but also builds upon Twist Bioscience's broader advances in the field. The company's prior work in developing engineered immune cells to target type 1 diabetes demonstrates its dual focus on both leveraging and safeguarding biotechnology’s potential, as seen in its approach to novel solutions for disease treatment.